These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38705932)

  • 1. Trends in Adverse Event Reporting Before and After the Introduction of the Med Safety App in Nigeria.
    Elemuwa UG; Bitrus F; Oreagba IA; Osakwe AI; Abiodun AS; Onu K; Abubakar A; Faniyi AE; Etuk V; Yuah D; Momodu R; Adeyeye CM
    Pharmaceut Med; 2024 May; 38(3):251-259. PubMed ID: 38705932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Retrospective Review of Serious Adverse Drug Reaction Reports in the Nigerian VigiFlow Database from September 2004 to December 2016.
    Ogar CK; Abiola A; Yuah D; Ibrahim A; Oreagba IA; Amadi EC; Adeyeye MC; Oshikoya KA
    Pharmaceut Med; 2019 Apr; 33(2):145-157. PubMed ID: 31933250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics, Quality and Contribution to Signal Detection of Spontaneous Reports of Adverse Drug Reactions Via the WEB-RADR Mobile Application: A Descriptive Cross-Sectional Study.
    Oosterhuis I; Taavola H; Tregunno PM; Mas P; Gama S; Newbould V; Caster O; Härmark L
    Drug Saf; 2018 Oct; 41(10):969-978. PubMed ID: 29761281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Facilitators and Barriers to Uptake of the Med Safety Mobile App for Adverse Drug Reaction Reporting by Health Workers in Uganda: A Qualitative Study.
    Kiguba R; Zakumumpa H; Ndagije HB; Mwebaza N; Ssenyonga R; Tregunno P; Harrison K; Pirmohamed M
    Drug Saf; 2023 Jun; 46(6):565-574. PubMed ID: 37097426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancing Pharmacovigilance in Sub-Saharan Africa Through Training and Mentoring: A GSK Pilot Initiative in Malawi.
    Jusot V; Chimimba F; Dzabala N; Menang O; Cole J; Gardiner G; Ofori-Anyinam O; Oladehin O; Sambakunsi C; Kawaye M; Stegmann JU; Guerra Mendoza Y
    Drug Saf; 2020 Jun; 43(6):583-593. PubMed ID: 32239447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse Drug Reaction Reports Received Through the Mobile App, VigiBIP
    Montastruc F; Bagheri H; Lacroix I; Damase-Michel C; Chebane L; Rousseau V; Jouanjus E; Lapeyre-Mestre M; Durrieu G; Montastruc JL
    Drug Saf; 2018 May; 41(5):511-514. PubMed ID: 29270770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of the feasibility and usability of a proof of concept mobile app for adverse event reporting post influenza vaccination.
    Wilson K; Atkinson KM; Westeinde J; Bell C; Marty K; Fergusson D; Deeks SL; Crowcroft N; Bettinger JA
    Hum Vaccin Immunother; 2016 Jul; 12(7):1738-48. PubMed ID: 26905396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of completeness of suspected adverse drug reaction reports submitted to the mexican national pharmacovigilance centre: a cross-sectional period-prevalence study.
    Sánchez-Sánchez B; Altagracia-Martínez M; Kravzov-Jinich J; Moreno-Bonett C; Vázquez-Moreno E; Martínez-Núñez JM
    Drug Saf; 2012 Oct; 35(10):837-44. PubMed ID: 22924896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Smartphone-based mobile applications for adverse drug reactions reporting: global status and country experience.
    Fukushima A; Iessa N; Balakrishnan MR; Pal SN
    BMC Med Inform Decis Mak; 2022 May; 22(1):118. PubMed ID: 35501745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increasing Patient Engagement in Pharmacovigilance Through Online Community Outreach and Mobile Reporting Applications: An Analysis of Adverse Event Reporting for the Essure Device in the US.
    Bahk CY; Goshgarian M; Donahue K; Freifeld CC; Menone CM; Pierce CE; Rodriguez H; Brownstein JS; Furberg R; Dasgupta N
    Pharmaceut Med; 2015; 29(6):331-340. PubMed ID: 26635479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Data-Driven Identification of Adverse Event Reporting Patterns for Japan in VigiBase, the WHO Global Database of Individual Case Safety Reports.
    Wakao R; Taavola H; Sandberg L; Iwasa E; Soejima S; Chandler R; Norén GN
    Drug Saf; 2019 Dec; 42(12):1487-1498. PubMed ID: 31559542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of factors associated with completeness of spontaneous adverse event reporting in the United States: A comparison between consumer reports and healthcare professional reports.
    Toki T; Ono S
    J Clin Pharm Ther; 2020 Jun; 45(3):462-469. PubMed ID: 31765498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues.
    Bergvall T; Norén GN; Lindquist M
    Drug Saf; 2014 Jan; 37(1):65-77. PubMed ID: 24343765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The completeness of adverse drug reaction reports in South Africa: An analysis in VigiBase®.
    Matlala MF; Lubbe MS; Steyn H
    Afr J Prim Health Care Fam Med; 2023 Jan; 15(1):e1-e9. PubMed ID: 36744452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse drug reactions in Nigerian children: a retrospective review of reports submitted to the Nigerian Pharmacovigilance Centre from 2005 to 2012.
    Obebi Cliff-Eribo K; Sammons H; Star K; Ralph Edwards I; Osakwe A; Choonara I
    Paediatr Int Child Health; 2016 Nov; 36(4):300-304. PubMed ID: 26384567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dedicated mobile application for drug adverse reaction reporting by patients with relapsing remitting multiple sclerosis (Vigip-SEP study): study protocol for a randomized controlled trial.
    Defer G; Le Caignec F; Fedrizzi S; Montastruc F; Chevanne D; Parienti JJ; Peyro-Saint-Paul L
    Trials; 2018 Mar; 19(1):174. PubMed ID: 29523169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An analysis of the trends, characteristics, scope, and performance of the Zimbabwean pharmacovigilance reporting scheme.
    Masuka JT; Khoza S
    Pharmacol Res Perspect; 2020 Oct; 8(5):e00657. PubMed ID: 32930524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profile of adverse drug reaction reports in South Africa: An analysis of VigiBase® for the year 2017.
    Steyn H
    S Afr Med J; 2023 Jun; 113(6):26-33. PubMed ID: 37278262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.